Sandoz’s Enzeevu secures FDA approval for nAMD treatment
Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a primary cause of vision impairment among individuals over 50
Aarvik Therapeutics has announced that its collaboration partner ArriVent BioPharma opted to exclusively license their joint programme.
The territories include Japan, South Korea, and several Southeast Asian countries, including Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. CBT-001 is an investigational emulsified nintedanib ophthalmic formulation